A Comprehensive Bioinformatic Analysis of RNA-seq Datasets Reveals a Differential and Variable Expression of Wildtype and Variant UGT1A Transcripts in Human Tissues and Their Deregulation in Cancers

Dong Gui Hu,Shashikanth Marri,Julie-Ann Hulin,Ross A. McKinnon,Peter I. Mackenzie,Robyn Meech

DOI: https://doi.org/10.3390/cancers16020353

2024-01-14

Cancers

Abstract:The UGT1A locus generates over 60 different alternatively spliced transcripts and 30 circular RNAs. To date, v2 and v3 transcripts are the only variant UGT1A transcripts that have been functionally characterized. Both v2 and v3 transcripts encode the same inactive variant UGT1A proteins (i2s) that can negatively regulate glucuronidation activity and influence cancer cell metabolism. However, the abundance and interindividual variability in the expression of v2 and v3 transcripts in human tissues and their potential deregulation in cancers have not been comprehensively assessed. To address this knowledge gap, we quantified the expression levels of v1, v2, and v3 transcripts using RNA-seq datasets with large cohorts of normal tissues and paired normal and tumor tissues from patients with six different cancer types (liver, kidney, colon, stomach, esophagus, and bladder cancer). We found that v2 and v3 abundance varied significantly between different tissue types, and that interindividual variation was also high within the same tissue type. Moreover, the ratio of v2 to v3 variants varied between tissues, implying their differential regulation. Our results showed higher v2 abundance in gastrointestinal tissues than liver and kidney tissues, suggesting a more significant negative regulation of glucuronidation by i2 proteins in gastrointestinal tissues than in liver and kidney tissues. We further showed differential deregulation of wildtype (v1) and variant transcripts (v2, v3) in cancers that generally increased the v2/v1 and/or v3/v1 expression ratios in tumors compared to normal tissues, indicating a more significant role of the variants in tumors. Finally, we report ten novel UGT1A transcripts with novel 3′ terminal exons, most of which encode variant proteins with a similar structure to UGT1A_i2 proteins. These findings further emphasize the diversity of the UGT1A transcriptome and proteome.

oncology

What problem does this paper attempt to address?

This paper aims to solve the following problems:

1. **Evaluate the expression levels of UGT1A transcripts in normal human tissues and their inter - individual variations**: By analyzing large - scale RNA - seq data sets, the researchers evaluated the expression levels of the three main transcripts (v1, v2, and v3) produced by the UGT1A locus in different normal human tissues and explored the expression variation of these transcripts among individuals.

2. **Explore the abnormal expression of UGT1A transcripts in cancer**: The study further analyzed the expression patterns of these three transcripts in six different types of cancer (liver cancer, kidney cancer, colon cancer, stomach cancer, esophageal cancer, and bladder cancer), especially their differential expression between tumor tissues and paired normal tissues, in order to understand the potential roles of these transcripts in the occurrence and development of cancer.

3. **Discover new UGT1A transcripts**: In addition to the above - known transcripts, the study also discovered ten new UGT1A transcripts. These new transcripts contain new 3' - terminal exons, further revealing the diversity of the UGT1A transcriptome and proteome.

Through these studies, the paper hopes to provide a comprehensive understanding of the expression characteristics of UGT1A transcripts in normal tissues and cancer, as well as the potential impacts of these transcripts in drug metabolism and cancer biology.